Eupraxia Pharmaceuticals Inc (EPRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eupraxia Pharmaceuticals Inc (EPRX) has a cash flow conversion efficiency ratio of -0.037x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-4.51 Million ≈ $-3.26 Million USD) by net assets (CA$123.06 Million ≈ $89.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Eupraxia Pharmaceuticals Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Eupraxia Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Eupraxia Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Eupraxia Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eupraxia Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IVF Hartmann Holding AG
SW:VBSN
|
0.014x |
|
Beijing E-techstar Co Ltd
SHE:300513
|
-0.096x |
|
GemVax&KAEL Co.Ltd
KQ:082270
|
0.181x |
|
Castro
TA:CAST
|
-0.018x |
|
Corem Property Group AB (publ)
ST:CORE-B
|
0.001x |
|
Dahu Aquaculture Co Ltd
SHG:600257
|
0.074x |
|
Jiangsu Xinning Modern Logist
SHE:300013
|
0.206x |
|
Grupo Traxión S.A.B. de C.V
MX:TRAXIONA
|
0.047x |
Annual Cash Flow Conversion Efficiency for Eupraxia Pharmaceuticals Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Eupraxia Pharmaceuticals Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Eupraxia Pharmaceuticals Inc (EPRX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$45.77 Million ≈ $33.11 Million |
CA$-29.99 Million ≈ $-21.70 Million |
-0.655x | +97.24% |
| 2023-12-31 | CA$1.18 Million ≈ $851.15K |
CA$-27.92 Million ≈ $-20.19 Million |
-23.726x | -1335.90% |
| 2022-12-31 | CA$11.36 Million ≈ $8.22 Million |
CA$-18.78 Million ≈ $-13.58 Million |
-1.652x | -120.66% |
| 2021-12-31 | CA$19.55 Million ≈ $14.14 Million |
CA$-14.64 Million ≈ $-10.59 Million |
-0.749x | -4116.12% |
| 2020-12-31 | CA$-21.66 Million ≈ $-15.67 Million |
CA$-403.93K ≈ $-292.19K |
0.019x | -93.46% |
| 2019-12-31 | CA$-18.13 Million ≈ $-13.12 Million |
CA$-5.17 Million ≈ $-3.74 Million |
0.285x | -60.80% |
| 2018-12-31 | CA$-11.44 Million ≈ $-8.27 Million |
CA$-8.32 Million ≈ $-6.02 Million |
0.728x | +170.13% |
| 2017-12-31 | CA$5.11 Million ≈ $3.69 Million |
CA$-5.30 Million ≈ $-3.83 Million |
-1.038x | -- |
About Eupraxia Pharmaceuticals Inc
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unm… Read more